Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CX 1739

Next Previous
Drug Profile

CX 1739

Alternative Names: CX-1739

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; National Institute of Drug Abuse; RespireRx Pharmaceuticals
  • Class Antidementias; Mood stabilisers; Respiratory stimulants
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory insufficiency; Sleep apnoea syndrome
  • Preclinical Spinal cord injuries
  • Discontinued Attention-deficit hyperactivity disorder; Substance-related disorders

Most Recent Events

  • 20 Mar 2024 Pharmacodynamics data from a preclinical trial in Spinal cord injuries released by RespireRx Pharmaceuticals
  • 20 Mar 2024 RespireRx Pharmaceuticals plans a phase II trial in Spinal cord injuries in late 2024
  • 08 Jun 2023 Preclinical trials in Spinal cord injuries in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top